fda warning letters bpc-157 2024 2025 for medical device companies Explained The Warning Letter Wake-Up Call
Description
In the Phase 3 TRIUMPH-4 trial, 33% of participants on the 12 mg dose reported diarrhea compared to 13.4% on placebo (Wang et al., Syst Rev Meta-Analysis, 2025)
This can result in tissue death and require emergency surgery
Experimental vascular studies indicate that BPC-157 modulates endothelial nitric oxide synthase activity by altering the interaction between endothelial nitric oxide synthase and its regulatory binding partner caveolin-1 [1][2]
Fast Ireland delivery
